Compare IPCA Labs with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs JUBILANT LIFE SCIENCES - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS JUBILANT LIFE SCIENCES IPCA LABS/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 31.7 12.8 247.3% View Chart
P/BV x 6.6 2.4 276.6% View Chart
Dividend Yield % 0.2 0.6 29.4%  

Financials

 IPCA LABS   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    IPCA LABS
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
IPCA LABS/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,042898 116.0%   
Low Rs590618 95.6%   
Sales per share (Unadj.) Rs298.6572.0 52.2%  
Earnings per share (Unadj.) Rs35.036.2 96.6%  
Cash flow per share (Unadj.) Rs49.459.5 83.1%  
Dividends per share (Unadj.) Rs3.004.50 66.7%  
Dividend yield (eoy) %0.40.6 61.9%  
Book value per share (Unadj.) Rs247.1301.9 81.9%  
Shares outstanding (eoy) m126.35159.28 79.3%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.71.3 206.3%   
Avg P/E ratio x23.320.9 111.5%  
P/CF ratio (eoy) x16.512.7 129.6%  
Price / Book Value ratio x3.32.5 131.6%  
Dividend payout %8.612.4 69.0%   
Avg Mkt Cap Rs m103,108120,694 85.4%   
No. of employees `00013.42.4 562.4%   
Total wages/salary Rs m7,87419,260 40.9%   
Avg. sales/employee Rs Th2,807.038,120.6 7.4%   
Avg. wages/employee Rs Th585.88,058.4 7.3%   
Avg. net profit/employee Rs Th329.02,414.3 13.6%   
INCOME DATA
Net Sales Rs m37,73291,108 41.4%  
Other income Rs m577357 161.4%   
Total revenues Rs m38,30991,466 41.9%   
Gross profit Rs m6,90117,390 39.7%  
Depreciation Rs m1,8243,709 49.2%   
Interest Rs m1892,198 8.6%   
Profit before tax Rs m5,46511,840 46.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,0423,268 31.9%   
Profit after tax Rs m4,4225,770 76.6%  
Gross profit margin %18.319.1 95.8%  
Effective tax rate %19.127.6 69.1%   
Net profit margin %11.76.3 185.1%  
BALANCE SHEET DATA
Current assets Rs m23,77845,848 51.9%   
Current liabilities Rs m10,97520,897 52.5%   
Net working cap to sales %33.927.4 123.9%  
Current ratio x2.22.2 98.7%  
Inventory Days Days10457 182.7%  
Debtors Days Days6651 129.4%  
Net fixed assets Rs m20,36865,498 31.1%   
Share capital Rs m253159 158.6%   
"Free" reserves Rs m30,97147,930 64.6%   
Net worth Rs m31,22448,089 64.9%   
Long term debt Rs m1,40942,429 3.3%   
Total assets Rs m45,507114,685 39.7%  
Interest coverage x30.06.4 469.1%   
Debt to equity ratio x00.9 5.1%  
Sales to assets ratio x0.80.8 104.4%   
Return on assets %10.16.9 145.8%  
Return on equity %14.212.0 118.0%  
Return on capital %17.312.4 139.6%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30812,422 139.3%   
Fx outflow Rs m6,26617,227 36.4%   
Net fx Rs m11,042-4,805 -229.8%   
CASH FLOW
From Operations Rs m4,92311,215 43.9%  
From Investments Rs m-1,563-10,118 15.4%  
From Financial Activity Rs m-1,8326,574 -27.9%  
Net Cashflow Rs m1,5287,612 20.1%  

Share Holding

Indian Promoters % 45.9 45.6 100.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 11.4 8.7 131.0%  
FIIs % 25.3 21.2 119.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.1 82.5%  
Shareholders   36,892 23,815 154.9%  
Pledged promoter(s) holding % 2.1 15.9 13.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  WYETH LTD  ABBOTT INDIA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty Stocks Rally(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 0.2%.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 9, 2020 10:33 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS